Difference between revisions of "Trametinib (Mekinist)"
Warner-admin (talk | contribs) m (Text replacement - "manufacturer. Instead" to "manufacturer. Instead") |
m |
||
| Line 7: | Line 7: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| − | *[[Melanoma]] | + | *[[Melanoma,_BRAF-mutated|BRAF-mutated melanoma]] |
*[[Non-small cell lung cancer, BRAF-mutated|BRAF-mutated NSCLC]] | *[[Non-small cell lung cancer, BRAF-mutated|BRAF-mutated NSCLC]] | ||
| + | *[[Thyroid cancer]] | ||
==Patient drug information== | ==Patient drug information== | ||
| Line 36: | Line 37: | ||
[[Category:Melanoma medications]] | [[Category:Melanoma medications]] | ||
[[Category:Non-small cell lung cancer medications]] | [[Category:Non-small cell lung cancer medications]] | ||
| + | [[Category:Thyroid cancer medications]] | ||
[[Category:Drugs FDA approved in 2013]] | [[Category:Drugs FDA approved in 2013]] | ||
Revision as of 17:38, 4 January 2018
General information
Class/mechanism: Reversible MEK1 (mitogen-activated extracellular signal regulated kinase 1) and MEK2 kinase inhibitor. MEK proteins are upstream and affect cellular proliferation by modulating the activity of the ERK (extracellular signal-related kinase) pathway. BRAF V600E mutations constitutively activate the BRAF pathway, which includes MEK1 and MEK2. By inhibiting MEK1 and MEK2, trametinib inhibits tumor cell growth that would otherwise be stimulated by constitutive activation from certain BRAF mutations.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp,UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
History of changes in FDA indication
- 5/29/2013: FDA approved "for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test."[1]
- 1/10/2014: FDA approved in combination with Dabrafenib (Tafinlar) "for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test."[1]
- 6/22/2017: FDA approved in combination with Dabrafenib (Tafinlar) "for patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test."
Also known as
- Code names: GSK-1120212, GSK1120212, JTP-74057
- Generic name: trametinib dimethyl sulfoxide
- Brand name: Mekinist